9 results
8-K
EX-99.1
PRAX
Praxis Precision Medicines Inc
7 Nov 23
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results
7:35am
1 of the EMBRAVE study and preliminary data shared at our 2023 R&D Day showing solid improvement to reduce seizures, while PRAX-562 and PRAX-628 … in the first half of 2024.
In October 2023 at its R&D Day, Praxis shared additional analyses from the Essential1 data set that continue to support
8-K
PRAX
Praxis Precision Medicines Inc
2 Oct 23
Other Events
1:27pm
, Praxis Precision Medicines, Inc. (the “Company”) provided an update on its clinical portfolio at the Company's R&D Day. The Company shared
8-K
EX-99.1
PRAX
Praxis Precision Medicines Inc
9 Aug 23
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results
8:27am
in measures of qEEG activity at all doses with first administration
Praxis will hold an R&D Portfolio Day on October 2
Cash of $124.3 million … expect to read out by the end of the year. We are planning to hold an R&D portfolio day on October 2 to elaborate on our science and clinical
8-K
EX-99.1
PRAX
Praxis Precision Medicines Inc
3 Nov 21
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2021 Financial Results
7:04am
. The increase in R&D expenses of approximately $20.4 million was primarily attributable to $10.9 million in increased expenses related to our clinical-stage
8-K
EX-99.1
cplciokjgx7dy
16 Aug 21
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2021 Financial Results
8:04am
8-K
EX-99.1
1bfr3d
11 May 21
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2021 Financial Results
8:11am
10-K
8qctojnj1nreivxa
17 Mar 21
Annual report
8:33am
8-K
EX-99.1
9zt6my
17 Mar 21
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
7:17am
- Prev
- 1
- Next